Saint Etienne De Montluc

Researchers are evaluating sotatercept as a potential treatment for pulmonary arterial hypertension (PAH), a condition where blood vessels in the lungs thicken and narrow, causing high blood pressure in the lungs and overworking the heart. PAH symptoms include difficulty breathing and reduced ability to be active. Current standard treatments address symptoms but do not stop disease progression. This Phase 3 study focuses on the long-term safety and tolerability of sotatercept when added to standard PAH therapy. Participants in this long-term follow-up study receive sotatercept through subcutaneous injections every three weeks. Only individuals who completed prior sotatercept PAH studies without early discontinuation may join. This study continues the observation and assessment of participants over an extended period to learn about the effects and safety of sotatercept combined with background PAH treatments. During the study, participants will be regularly monitored for adverse events, treatment discontinuations, and the presence of anti-drug antibodies for up to approximately 90 months. Laboratory tests will evaluate blood components such as platelets, hemoglobin, creatinine, bilirubin, and liver enzymes. Changes from baseline in body weight, blood pressure, and electrocardiogram readings will also be tracked. The study involves adherence to visit schedules and compliance with study procedures to ensure comprehensive long-term safety data collection.

Researchers are evaluating the effectiveness and safety of RO7837195 in adults with moderately to severely active ulcerative colitis who have not responded well or tolerated conventional or advanced treatments. This Phase IIb study aims to compare RO7837195 to a placebo during the initial treatment phase and then monitor all participants receiving the active drug to assess clinical remission at 12 weeks. The study includes a screening period lasting up to 5 weeks, followed by a 12-week induction phase where participants receive either RO7837195 or a matching placebo according to a specified schedule. After this induction phase, all participants enter a 40-week active treatment extension where they receive RO7837195 regardless of their earlier response. A safety follow-up period occurs after the last dose to continue monitoring participant health. Participants will undergo assessments throughout the study to measure clinical remission at week 12 and to monitor safety and pharmacokinetics. Researchers will collect data on symptoms, treatment effects, and any side effects experienced. The total participation involves multiple phases designed to carefully evaluate the long-term impact and safety of RO7837195 in ulcerative colitis management.

The trial focuses on children, adolescents, and young adults under 22 years with newly diagnosed intracranial ependymoma, a type of brain tumor. It aims to improve patient outcomes by standardizing diagnosis and treatment, and by enhancing understanding of the disease's biology to guide future therapies. Patients are classified into three groups based on age, tumor location, and surgery results to test different treatment methods. Treatment varies by group. Patients aged over 12 months and under 22 years with complete tumor removal receive conformal radiotherapy followed by either 16 weeks of chemotherapy with VEC-CDDP or observation. Those with remaining disease receive chemotherapy with VEC or VEC plus high-dose methotrexate, conformal radiotherapy, and possibly an extra radiation boost if the tumor persists. Children younger than 12 months or those who cannot have radiotherapy receive intense chemotherapy with or without valproate. Patients not meeting these criteria join a registry for observation. Participants undergo central reviews of imaging and pathology to confirm diagnosis and tumor status. Assessments include MRI scans and biological marker evaluation. Treatment response, disease progression, and survival are tracked up to 4.5 years, with key outcomes including tumor removal success, progression-free survival, and number of responders at 15 months. Safety and adherence are monitored throughout treatment and follow-up.